SCHEMBL18800809

SCHEMBL18800809

COc1cc(/C=C/C(=O)O[C@H]2Cc3cc4ccc(=O)oc4cc3OC2(C)C)ccc1O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 1/20 0.65
▸ GAA P10253 3/20 0.52
▸ PTPN1 P18031 2/20 0.52
▸ MGAM O43451 1/20 0.52
▸ SI P14410 1/20 0.52
▸ ACHE P22303 1/20 0.52
▸ MGAM2 Q2M2H8 1/20 0.52
▸ KDM4E B2RXH2 4/20 0.48
▸ MAPT P10636 1/20 0.48
▸ XBP1 P17861 1/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.48
▸ EPHX2 P34913 1/20 0.44
▸ CA12 O43570 4/20 0.43
▸ CA9 Q16790 4/20 0.43
▸ CA1 P00915 3/20 0.43
▸ CA7 P43166 3/20 0.43
▸ AKR1B1 P15121 2/20 0.43
▸ MCL1 Q07820 2/20 0.43
▸ CA13 Q8N1Q1 2/20 0.43
▸ CYP1A2 P05177 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29933810 1.00 MAOA (0.65) MAOAGAAPTPN1MGAMSI
SCHEMBL24756833 0.93 MAOA (0.67) MAOAGAAPTPN1MGAMSI
SCHEMBL30060767 0.92 MAOA (0.68) MAOAGAAPTPN1MGAMSI
SCHEMBL23335067 0.92 MAOA (0.68) MAOAGAAPTPN1MGAMSI
SCHEMBL4744259 0.90 MAOA (0.69) MAOAGAAPTPN1MGAMSI
SCHEMBL4744257 0.90 MAOA (0.69) MAOAGAAPTPN1MGAMSI
SCHEMBL24758311 0.90 MAOA (0.65) MAOAGAAPTPN1MGAMSI
SCHEMBL29933731 0.90 MAOA (0.65) MAOAGAAPTPN1MGAMSI
SCHEMBL4785737 0.89 MAOA (0.70) MAOAGAAPTPN1MGAMSI
SCHEMBL4785741 0.89 MAOA (0.70) MAOAGAAPTPN1MGAMSI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10280178-B2 Compound for inhibiting binding between DX2 protein and p14/ARF protein, and pharmaceutical composition for treating or preventing cancer disease containing same as effective ingredient PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) 2019-05-07 — — US disclosed
US-20170129904-A1 NEW COMPOUND FOR INHIBITING BINDING BETWEEN DX2 PROTEIN AND P14/ARF PROTEIN, AND PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER DISEASE CONTAINING SAME AS EFFECTIVE INGREDIENT PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) 2017-05-11 — — US disclosed
US-20170129904-A1 NEW COMPOUND FOR INHIBITING BINDING BETWEEN DX2 PROTEIN AND P14/ARF PROTEIN, AND PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER DISEASE CONTAINING SAME AS EFFECTIVE INGREDIENT PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) 2017-05-11 — — US disclosed
EP-3162803-A2 NEW COMPOUND FOR INHIBITING BINDING BETWEEN DX2 PROTEIN AND P14/ARF PROTEIN, AND PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER DISEASE CONTAINING SAME AS EFFECTIVE INGREDIENT Pusan National University Industry-University Cooperation Foundation (KR) 2017-05-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170129904-A1 NEW COMPOUND FOR INHIBITING BINDING BETWEEN DX2 PROTEIN AND P14/ARF PROTEIN, AND PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER DISEASE CONTAINING SAME AS EFFECTIVE INGREDIENT ARFIP2, G3BP2, TPX2 MAOA 4518/4885GAA 3451/4885PTPN1 1942/4885
US-10280178-B2 Compound for inhibiting binding between DX2 protein and p14/ARF protein, and pharmaceutical composition for treating or preventing cancer disease containing same as effective ingredient ARFIP2, G3BP2, TPX2 MAOA 4415/4885GAA 3444/4885PTPN1 1914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback